The company has raised $148 million so far and plans to raise the remaining $7 million by next month. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia.
Led by two Kite founders, the company launched with $300 million in VC funding in April and plans a registration trial of Servier's UCART19 and clinical development of its own allogeneic CAR-Ts next year.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Estimates of the incidence of FSHD, which has two types, range from 1-in-20,000 to 1-in-8,333, or about 870,000 cases worldwide.
No sooner did Heal close a Series A round in October that it added another $14.8 million from Fidelity Management and Research Company. Here are a few things that make this move interesting.